

TAF MEK melanoma - Contact us - HCP

Prescribing information

Speak to a Novartis representative

Source URL:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard . Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report , or alternatively email medinfo.uk@novartis.com or call 01276 698370.
UK February 2025 FA-11218005
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Submit
Your information will be used to put you in contact with a Novartis representative and handled in accordance with our Privacy Notice .
Work email
Name
area. Fields marked * below are mandatory.

https://www.pro.novartis.com/uk-en/medicines/oncology/tafinlar-mekinist/melanoma/contac